ArticleDermatology and therapy2026
Obesity and Early Biologic Failure in Psoriasis: An Italian Multicentre Retrospective Cohort Study.
Article in Dermatology and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionObesity may reduce biologic effectiveness in psoriasis, but its effect on specific reasons for treatment discontinuation is less well defined. We evaluated the association between obesity and biologic drug survival, with particular attention to primary failure and therapeutic class.
methodsThis retrospective multicentre cohort study included patients with plaque psoriasis treated with biologics at five Italian dermatology centres. Analyses were conducted at the treatment-line level using Kaplan-Meier methods and Cox proportional hazards models. Obesity was defined as body mass index (BMI) ≥ 30 kg/m
resultsOverall, 573 patients contributed 770 treatment lines; 193 of 562 patients with available BMI data (34.3%) were obese. Primary failure occurred in 17.0% of treatment lines from patients with obesity and 5.8% of treatment lines from patients without obesity (log-rank p < 0.001). In the adjusted Cox model, obesity was associated with a higher risk of primary failure (hazard ratio [HR] 2.75, 95% confidence interval [CI] 1.59-4.77). Each 5 kg/m
conclusionObesity was associated mainly with early biologic failure in psoriasis. The association was most evident with tumour necrosis factor-α inhibitors.
Indexed as
Identifiers
42870207What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.